Skip to main content
NEUROTECH INTERNATIONAL LIMITED logo

NEUROTECH INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · NTI ISIN · AU000000NTI9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 667 across all filing types
Latest filing 2020-02-16 Regulatory Filings
Country AU Australia
Listing ASX NTI

About NEUROTECH INTERNATIONAL LIMITED

https://neurotechinternational.com/

Neurotech International Limited is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for neurodevelopmental and neurological disorders. The company specializes in neuroprotective therapies, primarily targeting pediatric conditions with significant unmet medical needs, including Autism Spectrum Disorder (ASD), Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS), and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS). Its lead drug candidate, NTI164, is a proprietary, broad-spectrum cannabinoid formulation derived from a unique cannabis strain. NTI164 is engineered to exert anti-inflammatory and neuroprotective effects by modulating neuroinflammatory pathways. The company conducts clinical trials to establish the safety and efficacy of its treatments, aiming to provide transformative behavioral and functional improvements for patients.

Recent filings

Filing Released Lang Actions
Response to Appendix 4C Query 4 pages 276.4KB
Regulatory Filings Classification · 95% confidence The document is a letter from Neurotech International Ltd responding to an ASX query regarding the company's Appendix 4C Quarterly Report for the period ended 31 December 2019. The letter addresses questions about the company's negative operating cash flows, plans to raise further cash, and ability to continue operations. The document references the Appendix 4C quarterly report but does not contain the report itself or detailed financial statements. It is a regulatory response to a compliance query from the stock exchange, focusing on disclosure and continuous listing obligations. The document is not a full financial report, earnings release, or investor presentation, but rather a regulatory filing responding to a market compliance request. Therefore, it fits best under Regulatory Filings (RNS). The document length (9040 characters) and content confirm it is not a brief announcement or a full report but a detailed regulatory response.
2020-02-16 English
Ceasing to be a substantial holder 2 pages 530.5KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 605 Notice of ceasing to be a substantial holder under the Corporations Act 2001. It details changes in relevant interests and voting securities of a substantial shareholder, including dates and transaction details. This type of filing is a notification of changes in significant share ownership levels, which corresponds to a Major Shareholding Notification. The document is not a financial report, earnings release, or management report, but a regulatory disclosure about shareholding changes.
2020-02-03 English
Quarterly Report and Appendix 4C 8 pages 339.6KB
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "Quarterly report for the period ending 31 December 2019" and includes detailed financial data such as consolidated statements of cash flows, cash equivalents, payments to directors, financing facilities, and estimated cash outflows for the next quarter. It also references compliance with Listing Rule 4.7B and Australian Accounting Standards. The length of the document (15,000 characters) and the presence of substantive financial data and analysis confirm it is a comprehensive financial report for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). It is not merely an announcement or a certification, but contains actual financial statements and operational updates for the quarter. Q2 2020
2020-02-02 English
Cancellation of Mente Device from Australian TGA Register 2 pages 98.0KB
Regulatory Filings Classification · 95% confidence The document is an announcement from Neurotech International Limited regarding the cancellation of their Mente Autism Device from the Australian Therapeutic Goods Administration (TGA) Register. It details regulatory compliance issues and the impact of the cancellation on the company's operations and markets. There are no financial statements, earnings data, or detailed financial analysis present. The document is a regulatory announcement about a product registration status change, not a financial report or management discussion. It fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2020-01-27 English
Trading Halt 2 pages 160.7KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Neurotech International Limited regarding a trading halt requested under ASX Listing Rule 17.1. It states that the trading halt is pending an announcement related to correspondence from the Therapeutics Goods Administration about the registration of its Biofeedback system. The document is short (2032 characters) and is an announcement about a trading halt, not a financial report or detailed filing. It does not contain financial data, management discussion, or regulatory certifications. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for general regulatory announcements and compliance-related notices that do not fit other specific categories.
2020-01-23 English
Neurotech Expands Distribution to Taiwan 2 pages 71.9KB
Regulatory Filings Classification · 95% confidence The document is a company announcement dated 17 December 2019 about Neurotech International Limited signing an exclusive distribution agreement with Holy Stone Healthcare for the Taiwan market. It discusses the partnership, product details, and future expectations but contains no financial statements, regulatory filings, or detailed financial data. The document is relatively short (3311 characters) and reads as a business update or press release rather than a formal financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Capital Update. It is not a voting result, board change, or legal proceeding. The content is best classified as a general regulatory announcement about a business development. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2019-12-16 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.